Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Initiation of pivotal phase III program of TWIN for acne vulgaris

Dec. 18, 2018

Topline results presented from phase I study of XCUR-17 in chronic plaque psoriasis

Dec. 18, 2018

Topadur Pharma discloses PDE5A inhibitors

Dec. 17, 2018

Lilly initiates phase I study of LY-3454738 for atopic dermatitis

Dec. 17, 2018

Nflection Therapeutics discovers MAPKK 1 inhibitors

Dec. 13, 2018

Phase II study of bermekimab in atopic dermatitis meets endpoints

Dec. 13, 2018

Novan reports fourth cohort data from phase II trial of SB-206 for molluscum contagiosum

Dec. 12, 2018

Phase II study of serlopitant demonstrates reduction of pruritus associated with psoriasis

Dec. 11, 2018

Novartis initiates phase III trials of ligelizumab for chronic spontaneous urticaria

Dec. 4, 2018

Sienna reports phase IIb topline data on SNA-120 in psoriasis

Dec. 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...